LABORATORY RESEARCH PIM Kinase Inhibitor AZD1208 for Treatment of MYC-Driven Prostate Cancer Scientists examined the effects of a novel oral PIM inhibitor, AZD1208, on prostate tumorigenesis and recurrence. AZD1208 inhibited tumorigenesis in tissue recombinants, Myc-CaP, and human prostate cancer xenograft models. PIM inhibition decreased c-MYC/Pim1 graft growth, decreased cellular proliferation, and increased apoptosis. [J Natl Cancer Inst] Abstract The Role of TXNDC5 in Castration-Resistant Prostate Cancer – Involvement of Androgen Receptor Signaling Pathway Scientists demonstrate that thioredoxin domain-containing protein 5 (TXNDC5) is up-regulated following long-term androgen-deprivation treatment and is highly overexpressed in castration-resistant prostate cancer tumors compared with hormone-naive prostate cancer (PCa) cases. Functionally, in vitro and in vivo studies demonstrated that TXNDC5 overexpression promotes the growth of both androgen-dependent and castration-resistant PCa xenografts. [Oncogene] Abstract Loss of JUNB/AP-1 Promotes Invasive Prostate Cancer Researchers show that the transcription factor JUNB/AP-1 limits prostate cancer progression. JUNB expression is increased in low-grade prostate cancer compared with normal human prostate, but downregulated in high-grade samples and further decreased in all metastatic samples. [Cell Death Differ] Abstract PRK1/PKN1 Controls Migration and Metastasis of Androgen-Independent Prostate Cancer Cells Scientists show that metastatic behavior of androgen-independent prostate tumor cells requires the protein-kinase-C-related kinase (PRK1/PKN1) in vitro and in vivo. PRK1 regulates cell migration and gene expression through its kinase activity, but does not affect cell proliferation. [Oncotarget] Full Article miR-223-3p Targeting SEPT6 Promotes the Biological Behavior of Prostate Cancer Investigators found microRNA (miR)-223-3p were up-regulated in prostate cancer tissues and then studied functional roles of miR-223-3p in prostate cancer using DU145, PC3 and LNCaP cell lines. [Sci Rep] Full Article Inhibition of Polo-Like Kinase 1 (Plk1) Enhances the Anti-Neoplastic Activity of Metformin in Prostate Cancer Researchers show that BI2536, a specific Plk1 inhibitor, acts synergistically with metformin in inhibiting prostate cancer cell proliferation. They also provide evidence that Plk1 inhibition renders prostate cancer cells carrying wild type p53 to be much more sensitive to low dose metformin treatment. [J Biol Chem] Abstract | Full Article Diosmin Induces Genotoxicity and Apoptosis in DU145 Prostate Cancer Cell Line Cyto- and genotoxicity of three selected flavonoid glycosides in DU145 prostate cancer cell line were investigated. Flavonoid glycosides decreased cancer cell number and proliferative activity in a different manner. [Toxicol In Vitro] Abstract Targeting Prostate Cancer Cell Metabolism: Impact of Hexokinase and CPT-1 Enzymes Researchers evaluated the involvement of hexokinase and CPT-1 in the cell growth and proliferation of human prostate cancer cell lines, PC3, and LNCaP-FGC-10. [Tumor Biol] Abstract MicroRNA-218 Inhibits Prostate Cancer Cell Growth and Promotes Apoptosis by Repressing TPD52 Expression Scientists explored the regulative role of miR-218, a tumor suppressing miRNA on tumor protein D52 (TPD52) expression and prostate cancer cell proliferation. They found the expression of miR-218 was significantly lower in prostate cancer specimens. [Biochem Biophys Res Commun] Abstract CLINICAL RESEARCH Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients with Prostate Cancer Scientists report the long-term outcome of a large active surveillance protocol in men with favorable-risk prostate cancer. Main outcome measures were overall and disease-specific survival, rate of treatment, and prostate-specific antigen failure rate in the treated patients. [J Clin Oncol] Abstract Neutrophil to Lymphocyte Ratio as a Prognostic Biomarker for Men with Metastatic Castration-Resistant Prostate Cancer Receiving First-Line Chemotherapy: Data from Two Randomized Phase III Trials Researchers investigated associations of the derived neutrophil to lymphocyte ratio and duration of initial androgen deprivation therapy with survival of men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy. [Ann Oncol] Abstract |